These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

279 related articles for article (PubMed ID: 29572282)

  • 1. Memory decline accompanies subthreshold amyloid accumulation.
    Landau SM; Horng A; Jagust WJ;
    Neurology; 2018 Apr; 90(17):e1452-e1460. PubMed ID: 29572282
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Relationships between flortaucipir PET tau binding and amyloid burden, clinical diagnosis, age and cognition.
    Pontecorvo MJ; Devous MD; Navitsky M; Lu M; Salloway S; Schaerf FW; Jennings D; Arora AK; McGeehan A; Lim NC; Xiong H; Joshi AD; Siderowf A; Mintun MA;
    Brain; 2017 Mar; 140(3):748-763. PubMed ID: 28077397
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Amyloid-β assessed by florbetapir F 18 PET and 18-month cognitive decline: a multicenter study.
    Doraiswamy PM; Sperling RA; Coleman RE; Johnson KA; Reiman EM; Davis MD; Grundman M; Sabbagh MN; Sadowsky CH; Fleisher AS; Carpenter A; Clark CM; Joshi AD; Mintun MA; Skovronsky DM; Pontecorvo MJ;
    Neurology; 2012 Oct; 79(16):1636-44. PubMed ID: 22786606
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparing positron emission tomography imaging and cerebrospinal fluid measurements of β-amyloid.
    Landau SM; Lu M; Joshi AD; Pontecorvo M; Mintun MA; Trojanowski JQ; Shaw LM; Jagust WJ;
    Ann Neurol; 2013 Dec; 74(6):826-36. PubMed ID: 23536396
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Florbetapir PET analysis of amyloid-β deposition in the presenilin 1 E280A autosomal dominant Alzheimer's disease kindred: a cross-sectional study.
    Fleisher AS; Chen K; Quiroz YT; Jakimovich LJ; Gomez MG; Langois CM; Langbaum JB; Ayutyanont N; Roontiva A; Thiyyagura P; Lee W; Mo H; Lopez L; Moreno S; Acosta-Baena N; Giraldo M; Garcia G; Reiman RA; Huentelman MJ; Kosik KS; Tariot PN; Lopera F; Reiman EM
    Lancet Neurol; 2012 Dec; 11(12):1057-65. PubMed ID: 23137949
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cognitive and neuroimaging features and brain β-amyloidosis in individuals at risk of Alzheimer's disease (INSIGHT-preAD): a longitudinal observational study.
    Dubois B; Epelbaum S; Nyasse F; Bakardjian H; Gagliardi G; Uspenskaya O; Houot M; Lista S; Cacciamani F; Potier MC; Bertrand A; Lamari F; Benali H; Mangin JF; Colliot O; Genthon R; Habert MO; Hampel H;
    Lancet Neurol; 2018 Apr; 17(4):335-346. PubMed ID: 29500152
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Temporal Dynamics of β-Amyloid Accumulation in Aging and Alzheimer Disease.
    Jagust WJ; Landau SM;
    Neurology; 2021 Mar; 96(9):e1347-e1357. PubMed ID: 33408147
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Amyloid deposition, hypometabolism, and longitudinal cognitive decline.
    Landau SM; Mintun MA; Joshi AD; Koeppe RA; Petersen RC; Aisen PS; Weiner MW; Jagust WJ;
    Ann Neurol; 2012 Oct; 72(4):578-86. PubMed ID: 23109153
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Improved power for characterizing longitudinal amyloid-β PET changes and evaluating amyloid-modifying treatments with a cerebral white matter reference region.
    Chen K; Roontiva A; Thiyyagura P; Lee W; Liu X; Ayutyanont N; Protas H; Luo JL; Bauer R; Reschke C; Bandy D; Koeppe RA; Fleisher AS; Caselli RJ; Landau S; Jagust WJ; Weiner MW; Reiman EM;
    J Nucl Med; 2015 Apr; 56(4):560-6. PubMed ID: 25745091
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Alzheimer Disease Signature Neurodegeneration and APOE Genotype in Mild Cognitive Impairment With Suspected Non-Alzheimer Disease Pathophysiology.
    Schreiber S; Schreiber F; Lockhart SN; Horng A; Bejanin A; Landau SM; Jagust WJ;
    JAMA Neurol; 2017 Jun; 74(6):650-659. PubMed ID: 28319241
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Amyloid β Deposition and Suspected Non-Alzheimer Pathophysiology and Cognitive Decline Patterns for 12 Years in Oldest Old Participants Without Dementia.
    Zhao Y; Tudorascu DL; Lopez OL; Cohen AD; Mathis CA; Aizenstein HJ; Price JC; Kuller LH; Kamboh MI; DeKosky ST; Klunk WE; Snitz BE
    JAMA Neurol; 2018 Jan; 75(1):88-96. PubMed ID: 29114732
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Subthreshold Amyloid Predicts Tau Deposition in Aging.
    Leal SL; Lockhart SN; Maass A; Bell RK; Jagust WJ
    J Neurosci; 2018 May; 38(19):4482-4489. PubMed ID: 29686045
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cerebrovascular resistance: effects on cognitive decline, cortical atrophy, and progression to dementia.
    Yew B; Nation DA;
    Brain; 2017 Jul; 140(7):1987-2001. PubMed ID: 28575149
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Amyloid-β imaging with Pittsburgh compound B and florbetapir: comparing radiotracers and quantification methods.
    Landau SM; Breault C; Joshi AD; Pontecorvo M; Mathis CA; Jagust WJ; Mintun MA;
    J Nucl Med; 2013 Jan; 54(1):70-7. PubMed ID: 23166389
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Parental History of Memory Impairment and β-Amyloid in Cognitively Unimpaired Older Adults.
    Seto M; Hohman TJ; Mormino EC; Papp KV; Amariglio RE; Rentz DM; Johnson KA; Schultz AP; Sperling RA; Buckley RF; Yang HS
    JAMA Neurol; 2024 Aug; 81(8):798-804. PubMed ID: 38884955
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Association between tau deposition and antecedent amyloid-β accumulation rates in normal and early symptomatic individuals.
    Tosun D; Landau S; Aisen PS; Petersen RC; Mintun M; Jagust W; Weiner MW;
    Brain; 2017 May; 140(5):1499-1512. PubMed ID: 28334939
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Association of β-Amyloid and Apolipoprotein E ε4 With Memory Decline in Preclinical Alzheimer Disease.
    Lim YY; Kalinowski P; Pietrzak RH; Laws SM; Burnham SC; Ames D; Villemagne VL; Fowler CJ; Rainey-Smith SR; Martins RN; Rowe CC; Masters CL; Maruff PT
    JAMA Neurol; 2018 Apr; 75(4):488-494. PubMed ID: 29356823
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Measurement of longitudinal β-amyloid change with 18F-florbetapir PET and standardized uptake value ratios.
    Landau SM; Fero A; Baker SL; Koeppe R; Mintun M; Chen K; Reiman EM; Jagust WJ
    J Nucl Med; 2015 Apr; 56(4):567-74. PubMed ID: 25745095
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Florbetapir F 18 amyloid PET and 36-month cognitive decline: a prospective multicenter study.
    Doraiswamy PM; Sperling RA; Johnson K; Reiman EM; Wong TZ; Sabbagh MN; Sadowsky CH; Fleisher AS; Carpenter A; Joshi AD; Lu M; Grundman M; Mintun MA; Skovronsky DM; Pontecorvo MJ; ;
    Mol Psychiatry; 2014 Sep; 19(9):1044-51. PubMed ID: 24614494
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Association of CSF Aβ, amyloid PET, and cognition in cognitively unimpaired elderly adults.
    Guo T; Shaw LM; Trojanowski JQ; Jagust WJ; Landau SM;
    Neurology; 2020 Oct; 95(15):e2075-e2085. PubMed ID: 32759202
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.